NeurAxis (NRXS) Competitors $3.11 -0.02 (-0.67%) As of 02:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRXS vs. HYPR, PDEX, NSPR, OBIO, FONR, ZJYL, EDAP, NTRB, VANI, and PSTVShould you be buying NeurAxis stock or one of its competitors? The main competitors of NeurAxis include Hyperfine (HYPR), Pro-Dex (PDEX), InspireMD (NSPR), Orchestra BioMed (OBIO), Fonar (FONR), Jin Medical International (ZJYL), EDAP TMS (EDAP), Nutriband (NTRB), Vivani Medical (VANI), and Plus Therapeutics (PSTV). These companies are all part of the "medical equipment" industry. NeurAxis vs. Its Competitors Hyperfine Pro-Dex InspireMD Orchestra BioMed Fonar Jin Medical International EDAP TMS Nutriband Vivani Medical Plus Therapeutics NeurAxis (NASDAQ:NRXS) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings. Do analysts recommend NRXS or HYPR? NeurAxis currently has a consensus price target of $7.00, suggesting a potential upside of 125.15%. Hyperfine has a consensus price target of $1.28, suggesting a potential downside of 35.02%. Given NeurAxis' stronger consensus rating and higher probable upside, equities research analysts clearly believe NeurAxis is more favorable than Hyperfine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeurAxis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Hyperfine 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more volatility & risk, NRXS or HYPR? NeurAxis has a beta of 3.18, indicating that its stock price is 218% more volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Which has preferable earnings & valuation, NRXS or HYPR? NeurAxis has higher earnings, but lower revenue than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurAxis$3.22M9.54-$14.63M-$0.99-3.14Hyperfine$10.80M14.37-$40.72M-$0.52-3.80 Is NRXS or HYPR more profitable? Hyperfine has a net margin of -364.54% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Hyperfine's return on equity.Company Net Margins Return on Equity Return on Assets NeurAxis-492.76% N/A -641.25% Hyperfine -364.54%-84.82%-69.39% Do insiders and institutionals hold more shares of NRXS or HYPR? 11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 26.4% of NeurAxis shares are owned by company insiders. Comparatively, 31.0% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer NRXS or HYPR? In the previous week, Hyperfine had 4 more articles in the media than NeurAxis. MarketBeat recorded 4 mentions for Hyperfine and 0 mentions for NeurAxis. Hyperfine's average media sentiment score of 0.25 beat NeurAxis' score of 0.00 indicating that Hyperfine is being referred to more favorably in the news media. Company Overall Sentiment NeurAxis Neutral Hyperfine Neutral SummaryHyperfine beats NeurAxis on 10 of the 16 factors compared between the two stocks. Get NeurAxis News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXS vs. The Competition Export to ExcelMetricNeurAxisElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.70M$41.97M$9.06B$10.57BDividend YieldN/AN/A5.69%4.71%P/E Ratio-1.693.7685.8527.33Price / Sales9.54209.65535.28199.85Price / CashN/A41.3637.9261.55Price / Book-11.512.7513.026.76Net Income-$14.63M-$2.66M$3.30B$275.79M7 Day Performance-2.54%1.10%4.59%2.37%1 Month Performance26.90%4.94%9.76%8.78%1 Year Performance2.95%169.57%84.98%35.35% NeurAxis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXSNeurAxis1.9944 of 5 stars$3.11-0.7%$7.00+125.2%+3.0%$30.70M$3.22M-1.6919HYPRHyperfine1.1024 of 5 stars$1.45-1.4%$1.28-11.5%+109.0%$115.51M$12.89M-2.79190News CoverageAnalyst ForecastPDEXPro-Dex3.1189 of 5 stars$33.85-0.1%$56.00+65.4%+25.5%$110.58M$66.59M12.54140News CoverageAnalyst ForecastNSPRInspireMD3.0041 of 5 stars$2.41-0.4%$4.50+86.7%-9.3%$100.55M$7.07M-3.2150News CoverageOBIOOrchestra BioMed2.927 of 5 stars$2.48+0.8%$13.50+444.4%-41.8%$95.06M$2.64M-1.364News CoverageAnalyst ForecastFONRFonar0.8572 of 5 stars$15.06-0.6%N/A-0.7%$93.98M$104.35M12.24480ZJYLJin Medical InternationalN/A$0.57-3.9%N/A-82.0%$92.08M$22.83M0.00245News CoverageAnalyst ForecastGap UpEDAPEDAP TMS3.2769 of 5 stars$2.29-4.2%$8.50+271.2%-17.5%$89.37M$69.18M-3.75230News CoverageAnalyst ForecastNTRBNutriband2.0933 of 5 stars$7.05-0.1%$13.00+84.4%+36.9%$84.97M$2.14M-2.4610News CoverageAnalyst ForecastVANIVivani Medical3.0399 of 5 stars$1.41+0.7%$4.00+183.7%+22.1%$82.94MN/A-3.1320Positive NewsPSTVPlus Therapeutics3.9101 of 5 stars$0.68-17.7%$7.88+1,051.8%-44.7%$82.50M$5.82M-0.3120Analyst ForecastGap Up Related Companies and Tools Related Companies Hyperfine Alternatives Pro-Dex Alternatives InspireMD Alternatives Orchestra BioMed Alternatives Fonar Alternatives Jin Medical International Alternatives EDAP TMS Alternatives Nutriband Alternatives Vivani Medical Alternatives Plus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXS) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeurAxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
